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Abstract: (120 words) 25 
Intraocular pressure (IOP) reduction is currently the only evidence-based treatment 26 
strategy for glaucoma. However, IOP control in some individuals is challenging. Despite 27 
optimal treatment, a significant proportion of individuals will progress, with loss of visual 28 
field, loss of driving vision, and impaired quality of life. A new modality that could 29 
augment current treatment and reduce the rate of neurodegeneration to preserve vision 30 
throughout life would be a major breakthrough. 31 
 32 
A vast number of studies have reported effective neuroprotection in animal models of 33 
glaucoma; however, translation to the clinic remains a major hurdle. Herein, we explore 34 
the therapeutic advancements in non-IOP dependent neuroprotection, research based 35 
upon potential pathogenic mechanisms, and propose strategies to improve the clinical 36 
translation of laboratory research in glaucoma.  37 
 38 
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1. Introduction 79 
Glaucoma refers to a group of ocular conditions united by a characteristic optic 80 
neuropathy and associated retinal ganglion cell (RGC) loss(1). The most common 81 
subtype is primary open-angle glaucoma (POAG).  Approximately 1 in 6 individuals 82 
with POAG will progress to bilateral blindness within 20 years of being diagnosed (2). 83 
Clinical and histopathological evidence together indicate that the primary site of 84 
pathology in glaucoma is the optic nerve head (ONH)(3–5).  Hence, glaucoma is 85 
primarily considered to be an axonopathy, with subsequent Wallerian degradation of the 86 
distal axon and loss of RGC somata and dendrites in the retinal ganglion cell layer(5–7).  87 
 88 
In the broadest sense, neuroprotection refers to the relative preservation of neuronal 89 
structure and/or function(8). For a chronic neurodegenerative disease such as POAG, 90 
neuroprotection is conceptualized as a reduction in the rate of neurodegeneration. 91 
Intraocular pressure (IOP) reduction in glaucoma is arguably a form of neuroprotection. 92 
In fact, it is currently the only clinically proven strategy for successful neuroprotection. 93 
However, it is more common to consider IOP reduction as a distinct strategy with the 94 
notion of neuroprotection referring to a non-IOP related treatment modality that 95 
effectively reduces the rate of glaucomatous neurodegeneration independent of the IOP. 96 
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 97 
Whilst the pathogenesis of glaucoma remains incompletely understood, a spectrum of 98 
possible mechanisms to explain RGC pathology have been proposed, including genetic 99 
determinants, trophic factor withdrawal and loss of electrical activity, defective axon 100 
transport, chronic intermittent ischaemia, metabolic / bioenergetic failure, exposure to 101 
reactive oxygen species, and excitotoxicity(9–11). Laboratory studies continue to 102 
advance our understanding of these underlying pathogenic contributors in glaucoma, 103 
which ultimately pave the way to the development of improved neuroprotective 104 
strategies and subsequent clinical translation (Figure 1).  105 
 106 
Figure 1: Neuroprotective Strategies in Glaucoma 107 
 108 
2. POAG Genetics 109 
POAG has a complex genetic basis with the ongoing discovery of new genetic loci that 110 














POAG(9,12). Genetic linkage analyses have identified several key chromosomal loci 112 
shown to contribute to POAG risk (namely, MYOC, WDR36, OPTN, TBK1, NTF4, 113 
ASB10, EFEMP1, IL20RB). Genome-wide associations studies have identified 114 
additional gene loci (including CDKN2B-AS1, TMCO1, CAV1/CAV2, SIX1/SIX6, 115 
LRP12/ZFPM2, ABCA1, AFAP1, GMDS, GAS7, PMM2, ARH-GEF12, TGFBR3, 116 
TXNRD3, ATXN2, FOXC1, and C12ORF23) and many other additional loci have been 117 
found that affect IOP (12–14).  Somatic mitochondrial DNA (mtDNA) mutations, 118 
which are not inherited but accumulated with increasing age, and mtDNA 119 
polymorphisms may also contribute to mitochondrial dysfunction in glaucomatous optic 120 
neuropathy(12,14). Furthermore, genes that are involved in cell cycle control and 121 
transforming growth factor-β (TGFβ) pathways have emerged as substantial risk loci for 122 
POAG(13).  123 
 124 
Rather than mutations in single modifier genes it appears that it is the presence of 125 
polymorphisms in different genes which ultimately modulates the disease phenotype in 126 
glaucoma(12). Retinal gene replacement may prove a useful therapeutic avenue, which 127 
could conceivably, then, pave the way for the future development of targeted and 128 
individualised treatment strategies for glaucoma.  129 
 130 
2.1. Genetic Therapy in POAG 131 
Genetic therapies primarily aim to correct a fundamental molecular basis of the disease 132 
in question or prevent the transmission of pathogenic mutations across generations(12). 133 
In the context of glaucoma, most of these approaches are at the early experimental 134 
phase. Aside from ethical considerations, major practical limitations exist when 135 
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considering the development of genetic therapies for glaucoma. Whilst there is an 136 
evolving range of tools available for retinal gene transfer, few to date have had a 137 
significant impact on RGC neuroprotection. This appears to be reflective of the 138 
challenges relating to gene transfer, penetration, precise localisation and binding to the 139 
intended target site or, in the case of viral vectors, the associated safety risks with 140 
insertional mutagenesis and potential immunogenic response(12,15).  141 
 142 
The delivery of genes encoding therapeutic proteins such as neurotrophic factors (for 143 
example, adeno-associated virus type 2 (AAV2) mediated delivery of brain derived 144 
neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF)) have been 145 
demonstrated to confer protection for RGCs in experimental models of retinal injury 146 
(16,17). Several pre-clinical studies investigating intravitreal injection of viral vectors 147 
carrying antiapoptotic genes have demonstrated protection against RGC and axonal loss 148 
in vivo(17–20). The augmentation of tissue antioxidant status, via intravitreal injection 149 
of viral vectors containing enzymes such as catalase or superoxide dismutase (SOD), for 150 
example, has been investigated and has indicated improved RGC survival in animal 151 
models of optic nerve crush and ischaemia/reperfusion damage(17,21–23). Furthermore, 152 
a clinical trial initiated in 2003 utilised short-term adenoviral vector expression of the 153 
cell cycle regulator p21 gene (encoding the CDKN1A protein) delivered before 154 
trabeculectomy surgery, with the intent of modulating wound healing(17). Pre-clinical 155 
studies in primates have already demonstrated that delivery of the virus prior to surgery 156 
maintained the trabeculectomy outflow pathway with minimal biodistribution outside 157 
the eye(17,24,25).  158 
 159 
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3. Neurotrophic Support 160 
Neurotrophic factors generally function through tyrosine kinase signalling to support 161 
the growth, survival, and repair of neurons(26).  Neurotrophic factors have been 162 
demonstrated to be strongly neuroprotective whilst promoting axon regeneration and 163 
enhancing neuronal cell function(9).  Given their promising results in other 164 
neurodegenerative diseases of the central nervous system, neurotrophic factors offer an 165 
attractive therapeutic option to pursue in glaucoma. 166 
 167 
Neurotrophic factors trialled for neurodegerative disease include: brain derived 168 
neurotrophic factor (BDNF) for amylotrophic lateral sclerosis (ALS), ciliary 169 
neurotrophic factor (CNTF) for ALS and for macular degeneration, glial derived 170 
neurotrophic factor (GDNF) for Parkinson’s disease, and nerve growth factor (NGF) for 171 
Alzheimer’s disease(17). However, none have succeeded in human trials(17). Oddone et 172 
al. (2017) found that both BDNF and NGF are reduced in the early and moderate stages 173 
of human glaucoma, and these could therefore act as potential biomarkers for early 174 
detection of glaucoma(27). NGF, CNTF, fibroblast growth factor 2 (bFGF) and BDNF 175 
have demonstrated efficacy in inhibiting RGC apoptosis in pre-clinical glaucoma 176 
models(28–30). Topical NGF therapy has recently been trialled in three patients with 177 
advanced glaucoma, improving several parameters of visual function(28).  178 
 179 
Neurotrophic factor efficacy can be enhanced by stimulating RGCs with electrical 180 
activity or pharmacologically elevating cyclic adenosine monophosphate (cAMP), 181 
which greatly potentiates the pro-survival and growth effects of neurotrophic factor 182 
treatment(9,31,32). Evidence has shown that the combined administration of trophic 183 
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factors is more effective for the survival of RGCs than the administration of each factor 184 
separately(33). Neurotech® has developed a polymeric device (NT-501) which can be 185 
surgically implanted beneath the pars plana and which contains a genetically modified 186 
human cell line which secretes CNTF(9). The CNTF is encapsulated into a semi-187 
permeable membrane, allowing it to diffuse out whilst evading potentially attacking 188 
immune system cells(9). Phase I clinical trials for NT-501 in glaucoma have been 189 
undertaken without serious adverse events (Clinical Trails USA NCT01408472) and 190 
Phase II clinical trials were established in 2016 (Clinical Trails USA NCT02862938).  191 
 192 
4. Stem Cell Therapy  193 
Stem cell therapy is gaining increasing interest and has the aim of regenerating 194 
endogenous cells in vivo to counteract damage caused by disease. Mesenchymal stem 195 
cells (MSCs) have shown promising results in regard to their neuroprotective potential 196 
in models of Parkinson’s disease, multiple sclerosis, spinal cord injury, and Alzheimer’s 197 
disease among others (12,16,34–39). The optic nerve is a favourable target for MSC 198 
therapy as it has the unique advantage of being somewhat contained and thereby 199 
protected from direct systemic immunological reaction(13), as well as being open to 200 
real-time monitoring in vivo via evolving technologies such as optical coherence 201 
tomography (OCT).  202 
 203 
MSCs are multipotent and therefore have the ability to differentiate into an array of 204 
cells. They are easy to source from adult bone marrow or human umbilical cord blood, 205 
and can be used without immune suppression(12,16,39,40). The neuroprotective and 206 
regenerative effects of MSCs are achieved through their ability to differentiate into 207 
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neurons and glial cells, promote endogenous neuronal growth, promote 208 
neuro/gliogenesis, encourage synaptic connection, reduce demyelination, induce 209 
oligodendrogenesis, stimulate angiogenesis, decrease apoptosis, reduce oxidative stress 210 
by lowering free radicals, modulate microglial activation, and suppress inflammatory 211 
responses(39). Ultimately the goal of stem cell therapy in the context of optic 212 
neuropathy is to recover vision via neuroregeneration of damaged or dead RGCs and 213 
their axons. 214 
 215 
4.1. Mesenchymal Stem Cells in Animal Studies 216 
MSC transplantation with neuroprotective effects has been trialled in a variety of animal 217 
models of optic nerve damage(12). Roubeix et al. (2015) used MSC transplantation in 218 
the anterior chamber of hypertensive rat eyes to demonstrate a rapid and long-lasting in 219 
vivo protective effect in peripheral RGC degeneration, achieved via improvement in 220 
trabecular meshwork integrity and function resulting in IOP reduction(40). Likewise, 221 
intravitreal MSC injection into hypertensive rat eyes demonstrated a neuroprotective 222 
effect on RGC axon survival yet had no effect on optic nerve damage(41). Repair and 223 
regeneration of axotomised RGC neurons was, however, demonstrated with MSC 224 
grafting into the site of optic tract transection at the level of the lateral geniculate 225 
nucleus in neonatal rats(42). Zhao et al. (2011) and Jiang et al. (2013) demonstrated the 226 
protective effect of intravitreal delivery of human umbilical cord stem cells on optic 227 
nerve crush injury in rats on RGC survival, optic nerve function, improved pathological 228 
changes in the rat retina and up-regulation in the expression of trophic factors BDNF 229 
and GDNF(43,44).  230 
 231 
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The attenuation of RGC death by MSC transplantation is largely attributed to the 232 
extended release of trophic factors by the transplanted cells, such as CNTF, bFGF, 233 
GDNF, HGFα and BDNF(33,43,45,46). Recently, platelet-derived growth factor 234 
produced by human MSCs has been shown to have a strong neuroprotective action on 235 
human RGCs. Ref (Osborne et al Neuroprotective Effects of Human Mesenchymal 236 
Stem Cells and Platelet-Derived Growth Factor on Human Retinal Ganglion Cells. 237 
  CNTF is a potent RGC survival factor and bFGF is a stimulator of axonal growth(45). 238 
Several studies have demonstrated that despite the significant RGC neuroprotection 239 
afforded by intravitreal MSC injection, these latter cells did not migrate well and mostly 240 
remained present in the vitreous cavity and inner limiting membrane with minimal 241 
penetration through to the ganglion cell layer(33,41,45). Further, there was limited 242 
differentiation of MSCs to retinal neuronal cells or RGC with functional axons and this 243 
was reflective of poor integration of grafted MSCs into the retinal tissue or optic 244 
tract(33,42,45). Therefore stem cells used as a vector for delivery and secretion of 245 
neurotrophic factors to repair damaged RCGs could be more advantageous than their 246 
seemingly limited ability to integrate and differentiate to repopulate retinal neuronal 247 
tissue(46). 248 
 249 
4.2. Mesenchymal Stem Cells in Clinical Studies  250 
Intraocular injection of MSCs for the treatment of retinal and optic nerve disease are 251 
currently being investigated in a large open-label non-randomised efficacy clinical trial, 252 
the Stem Cell Ophthalmology Treatment Study (SCOTS; Clinical Trial USA Identifier 253 
NCT01920867)(12,16,47). Whilst the study is currently in progress, preliminary reports 254 
have detailed impressive results in isolated cases of optic neuritis and Leber’s 255 
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Hereditary Optic Neuropathy(48,49). Although the level of evidence is not robust, these 256 
clinical results motivate ongoing research with MSCs as therapy for ophthalmologic 257 
mitochondrial disease with potential translation to glaucoma. Two registered phase 1 258 
clinical trials specific to the treatment of glaucoma with MSCs are currently in progress: 259 
The Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma Study 260 
(Clinical Trials USA Identifier NCT02330978, estimated study completion date 261 
December 2016, no published results available), Effectiveness and Safety of Adipose-262 
Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration study 263 
(Clinical Trials USA Identifier NCT02144103, estimated study completion date January 264 
2019).  265 
 266 
4.3. Human Embryonic Stem Cells 267 
The use of human embryonic stem cells (hESCs) is more ethically controversial despite 268 
the advantage of these pluripotent cells being able to differentiate into all derivatives of 269 
the three embryonic layers(12). Photoreceptor generation from hESCs has progressed 270 
more rapidly than has generation of RGCs. Sluch et al. (2015) described a cell culture 271 
protocol for the differentiation of hESCs to highly purified, functional RGCs using the 272 
CRISPR-engineered reporter cell line, including a comprehensive characterisation of 273 
the cells obtained(49). Pre-clinical studies have previously demonstrated the ability of 274 
retinal cells derived from hESCs to survive, integrate into the host retina, and mediate 275 
light responses(51,52). Whilst hESC technology is in essence still embryonic, with 276 
ethical and scientific challenges, it has the potential to revolutionalize the management 277 
of ocular neurodegenerative disease considered incurable through neuroregeneration of 278 
functioning retinal neurons.  279 
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 280 
5. Bioenergetic Protection  281 
Bioenergetic neuroprotection refers to supporting the neuronal energy requirements at a 282 
cellular level which includes protecting cells against downstream metabolic failure to 283 
circumvent apoptosis which causes consequent neurodegeneration. This approach is 284 
gaining momentum in pre-clinical glaucoma research with promising therapeutic 285 
translation on the horizon.  286 
 287 
5.1. Visual metabolic demands and RGC bioenergetics 288 
Visual processing is metabolically expensive, which makes retinal cells exquisitely 289 
sensitive to bioenergetic disturbance. The metabolic cost for the processing of sensory 290 
information by photoreceptors has been estimated at 106-107 ATP molecules for graded 291 
signals(53). Thus the process of phototransduction places intense energy demands upon 292 
photoreceptors, which derive nutrients and oxygen from the choroidal circulation. 293 
 294 
The optic nerve is formed by over one million RGC axons, which serve as a conduit 295 
between the retina and brain(10). The RGC axon has a tremendously long trajectory 296 
relative to the size of the cell body, upon which neuronal shuttling of cellular cargo 297 
occurs, which ultimately compounds the energy demands placed upon RGCs(10). 298 
Emerging evidence has strongly associated RGC mitochondrial dysfunction with retinal 299 
and optic nerve damage(54). Impaired axonal transport of mitochondria has been linked 300 
to RGC death and, given that the unmyelinated axons of RGCs in the pre-laminar retinal 301 
nerve fiber layer require a higher energy input, this may in part explain their 302 
vulnerability to metabolic injury(10,12). Ultimately RGC survival and function are 303 
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highly dependent on an intact energy supply and are therefore exquisitely sensitive to 304 
homeostatic disruptions such as anoxia or metabolic substrate decline(10,12). 305 
 306 
Light must pass through the entire thickness of the vertebrate retina to reach the 307 
photoreceptors, hence, the retina needs to be as transparent as possible. This means that 308 
within this tissue there must be a minimal level of blood vessel columns because these 309 
structures are relatively opaque. This optical requirement for relatively limiting 310 
vasculature, coupled with the large energy demands of the retina make it particularly 311 
vulnerable to insults involving alterations in the available blood supply (55). 312 
Furthermore, the blood supply of the optic nerve head (ONH) is primarily derived from 313 
the choroid and is thus susceptible to pressure differentials within the tissue. These 314 
unique vascular compromises inherent to the retina ultimately make the ONH more 315 
vulnerable to ischaemia which in turn contributes to neurodegeneration in chronic 316 
glaucoma(56).   317 
 318 
The brain and retina are both dependent upon glucose metabolism to produce adenosine 319 
triphosphate (ATP), but there are fundamental differences between retinal and cerebral 320 
energy metabolism(57). Akin to the brain, much of the energy required for visual 321 
functioning is derived from oxidative metabolism coupled to ATP synthesis(12,58). Yet 322 
unlike the brain, the isolated mammalian retina also derives a considerable amount of 323 
ATP from the conversion of glucose to lactate, even in the presence of oxygen(10,57). 324 
This has the advantage that in the absence of oxygen, the mammalian retina has the 325 
remarkable ability to maintain most of its ATP requirements via glycolysis(10,57). 326 
However, the precise contribution of both glycolysis and oxidative phosphorylation to 327 
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energy metabolism in RGCs and their axons remains unclear and is likely to be both 328 
species dependent and dependent upon the level of retinal vasculature(10). 329 
 330 
5.2. Consequences of Retinal Energy Failure 331 
5.2.1. Reactive Oxygen Species 332 
As a downstream consequence of mitochondrial bioenergetic failure, oxidative stress 333 
has received considerable attention for its contribution to RGC injury. Generation of 334 
reactive oxygen species (ROS), a series of intracellular by-products derived from 335 
mitochondrial respiration, is a process which is usually tightly regulated under normal 336 
physiological conditions. The antioxidant response is typically carried out by enzymes 337 
such as SOD, catalase, glutathione peroxidase, thioredoxin, peroxiredoxin as well as 338 
non-enzymatic compounds such as retinol and carotenoids (together comprising vitamin 339 
A), ascorbic acid (vitamin C), tocopherols (vitamin E) and melatonin(12). The increased 340 
production of ROS from dysfunctional mitochondria in disease conditions, however, 341 
leads to chronic oxidative damage which can contribute to cellular dysfunction and 342 
consequent neurotoxicity(12). Apart from production via mitochondrial respiratory 343 
chain reactions, there is also a simultaneous increase in extra-mitochondrial production 344 
of ROS in the cytosol(59). This leads to oxidative deactivation of many enzymes 345 
involved in, for example, regulation of glycolysis, in particular glyceraldehyde-3-346 
phosphate dehydrogenase (GAPDH) and pyruvate kinase(59). Rhodopsin and other 347 
photosensitizers also augment the production of ROS in the retina during photopic 348 
vision, which, by definition, involves exposure of the retina to light(59).  349 
 350 
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The retina is exquisitely sensitive to oxidative damage given its relatively high level of 351 
oxygen consumption(59,60). Consequently, oxidative stress is a pathogenic feature of 352 
many vision-impairing diseases, including glaucoma, age-related macular degeneration 353 
(ARMD), diabetic retinopathy, and uveoretinitis(12,59,60). However, dysfunctional, but 354 
not dead, RGCs may be amenable to neurorecovery with early intervention that targets 355 
potential mitochondrial dysfunction and elevated oxidative stress, via minimising the 356 
generation or accumulation of ROS(8,12).  357 
 358 
5.2.2. Excitotoxicity  359 
The pivotal role of excitotoxicity in neurodegenerative disease is gaining momentum 360 
and understanding its role in the treatment of optic neuropathies is receiving increasing 361 
attention. Excitotoxicity refers to cell death resulting from the toxic actions of excitatory 362 
amino acids(61,62). The stimulation of glutamate receptors, interleukin-1 receptors (IL-363 
1Rs), JUN-linked receptors, and tumour necrosis factor receptors (TNFRs) triggers 364 
retinal neurons to undergo apoptosis through a cascade of cellular signalling events 365 
which in turn promote the release of cytochrome c and which activate the caspase 366 
pathways(13). Glutamate is the major excitatory neurotransmitter in the mammalian 367 
central nervous system and through prolonged exposure contributes substantially to the 368 
injury and death of neurons with the associated excessive influx of ions into the 369 
cell(61). The major ionotropic receptors activated by glutamate are N-methyl-D-aspartic 370 
acid (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and kainic 371 
acid (KA) receptors(61). Sustained activation (“overactivation”) of glutamate receptors 372 
impairs cellular calcium homeostasis and activates nitric oxide synthesis, generation of 373 
free radicals and programmed cell death (Figure 2B)(61,62). Therapies targeting 374 
 17 
excitotoxicity, such as memantine and brominidine, have thus been explored for their 375 
therapeutic application in glaucoma.  376 
 377 
5.2.2.1. Memantine 378 
Memantine is a non-competitive NMDA receptor antagonist which blocks glutamate 379 
excitotoxicity and is commonly used in the treatment of moderate to severe Alzheimer’s 380 
disease(9). Several animal glaucoma models have shown that memantine is protective 381 
against RGC loss(9,13,16,63,64). However, large-scale multicentre, randomised double-382 
masked placebo-controlled Phase III clinical trials conducted to test the efficacy of oral 383 
memantine for glaucoma failed to show any statistical benefit compared to placebo in 384 
reducing visual field progression(13,16). 385 
 386 
5.2.2.2. Brimonidine 387 
Brimonidine, an α2-adrenergic receptor agonist, is commonly used to lower IOP in 388 
glaucoma and is FDA approved for systemic administration. It has been demonstrated to 389 
protect RGCs in animal models of optic nerve damage independent of its effect on IOP 390 
by up-regulating anti-apoptotic factors and by blocking cellular toxicity induced by 391 
mitochondrial oxidative stress(2,8,14,16,107,108). This is thought to be achieved 392 
through the modulation of glutamate-induced excitotoxicity, vascular regulation via 393 
inhibition of nitric oxide synthase or the endothelin pathway, oxidative stress, and 394 
inhibition of glial activity(16). It has been demonstrated in clinical trials that 395 
brimonidine monotherapy lowered the incidence of visual field progression compared 396 
with timolol in treated patients (9 vs 30%) in the Low Pressure Glaucoma Study Group 397 
over a period of 30 months despite similar IOP lowering effects(9,13,16,65). Yet this 398 
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study was limited by its small sample size and considerable drop out rate in the 399 
brimonidine group(13,65). Topical brimonidine 0.2% applied over 3 months has also 400 
been found to improve contrast sensitivity, in comparison to no improvement with 401 
timolol therapy, despite similar IOP lowering effects(66). A meta-analysis comparing 402 
timolol to brimonidine also confirmed no significant difference in IOP lowering 403 
effect(67). Tsai et al.(2005) described a statistically significant reduction in retinal 404 
nerve fibre layer damage following the use of brimonidine 0.2% compared with timolol 405 
0.5% in ocular hypertensive patients over one year, independent of IOP reduction(68). 406 
These results suggest that brimonidine provides a non-IOP related neuroprotective 407 
effect.  408 
 409 
5.3. Targeting Energy Metabolism 410 
5.3.1. Glycolysis  411 
Glycolysis is the oxygen independent metabolic pathway, which takes place in the 412 
cytosol of cells, to convert glucose into pyruvate to generate two ATP molecules per 413 
starting glucose. In the presence of oxygen, pyruvate is able to then enter the Kreb’s 414 
cycle to generate 32-36 net ATP molecules within mitochondria, or in anaerobic 415 
conditions is instead converted to lactate in the presence of nicotinamide adenine 416 
dinucleotide (NAD+ or NADH)(Figure 2A). Whilst still in its infancy, experimental 417 
trials have demonstrated that through the manipulation of the glycoloytic pathway via 418 
substrate supplementation, RGC function and survival can be prolonged thereby 419 
affording a degree of neuroprotection in glaucoma(54,59,60,69). 420 
 421 
5.3.1.1. Glucose 422 
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Using rat retinal explants Winkler et al. (1981) demonstrated that the majority of retinal 423 
ATP production can be maintained under conditions of oxygen deprivation provided 424 
that there is an abundance of glucose(70). In vitro the neuroprotective effect of glucose 425 
administration has been demonstrated to be predominantly due to glycolytic ATP 426 
production which suggests that RGCs can up-regulate glycolysis during ischaemia to 427 
generate ATP(71). Studies have demonstrated that elevated vitreous glucose levels 428 
provide robust neuroprotection of RGC somata and axons against experimental retinal 429 
ischaemic injury(57,72) and experimental glaucoma(69). 430 
 431 
It was subsequently shown in clinical trials that contrast sensitivity was temporarily 432 
recovered in pseudophakic individuals with severe POAG after topical glucose 433 
application(73). Whilst glucose may provide a considerable degree of neuroprotection 434 
or recovery to damaged but not yet dead RGCs in the short term, long- term elevated 435 
vitreous glucose levels would possibly cause deleterious ocular complications such as 436 
cataract or diabetic-type retinal disease.  437 
 438 
5.3.1.2. Pyruvate 439 
Pyruvate is an endogenous alpha keto acid metabolite that protects against oxidative 440 
stress whilst simultaneously providing energy substrate support(59,60,74)(Figure 2C). 441 
Under normal circumstances, when oxygen is abundant, pyruvate is converted to acetyl 442 
CoA, which then enters the Kreb’s cycle to contribute to the formation of substrates and 443 
electron donors for oxidative phosphorylation (OXPHOS) generating about 32 ATP 444 
molecules(71). In the face of oxygen deprivation, pyruvate is instead converted to 445 
lactate by lactate dehydrogenase (LDH) to regenerate nicotinamide adenine dinucleotide 446 
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(NAD+)(71,74). It has been proposed that pyruvate could facilitate glycolysis by 447 
recycling of NAD+ required for the continued activity of the glycolytic pathway(59). 448 
By scavenging various ROS species, pyruvate is also able to inhibit oxidative stress. 449 
This prevents the toxic reactions of lipid peroxidation and loss of tissue thiols, thereby 450 
protecting the retina against further insult whilst supporting glycolysis(59,74). Pyruvate 451 
also reduces the blood glutamate level, thereby reducing glutamate-induced 452 
neurotoxicity, prevents neuronal network hyperexcitability, and exhibits potent anti-453 
inflammatory action(74).  454 
 455 
Evidence is accumulating to support the neuroprotective effect of pyruvate in 456 
experimental models of neurodegenerative disease, such as ischaemic brain injury, 457 
hypoglycaemic brain injury, Huntington’s disease, neuroblastoma, closed head injury, 458 
and Parkinson’s disease(75–83). Preliminary in vivo experiments by Hegde et al.(2008 459 
and 2010) demonstrated that pyruvate substantially promotes glycolysis in the retina in 460 
the face of ROS-induced inhibition(59,60). This could be explained by the inhibition of 461 
oxidative inactivation of –SH containing enzymes such as GAPDH and pyruvate kinase, 462 
and the continued regeneration of NAD+ (produced during the reduction of pyruvate to 463 
lactate by LDH) with consequent stimulation of the oxidation of glyceraldehyde-3-464 
phosphate to 1,3 diphosphoglycerate by GAPDH dependent on NAD+ availability(59).  465 
 466 
Figure 2: Cellular Mechanism of Neurodegeneration and Pyruvate 467 






(A) Normal cellular respiration: Under normal conditions glucose enters the cell 472 
through the transmembrane glucose transporter (GLUT) and is metabolised to pyruvate 473 
via glycolysis. If oxygen is abundant, pyruvate enters the tricarboxylate acid (TCA or 474 
‘Kreb’s’) cycle where it is metabolised via oxidative phosphorylation to form an 475 
abundance of ATP. Under anaerobic conditions pyruvate is instead preferentially 476 
converted to lactate, by lactate dehydrogenase (LDH), in the presence of NADH. 477 
Conversely, lactate can also enter cells through the monocarboxylate transporter 478 
(MCT) and can be converted to pyruvate by LDH in the presence of NAD+. 479 
(B) Pathology of neurodegeneration: Both oxidative stress and extracellular glutamate 480 
trigger excitotoxicity, which contributes to neuronal degeneration. Glutamate 481 
accumulation triggers an influx of excessive calcium into cells. Reactive oxygen species 482 
accumulate and contribute to neuroinflammation and oxidative stress. DNA damage is 483 
induced by ROS leading to the overactivation of poly-ADP ribose polymerase-1 (PARP-484 
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1) causing depletion of cytostolic NAD+. Reduced NAD+ inhibits glycolysis with 485 
subsequent decline in mitochondrial ATP production, as well as limiting the conversion 486 
of lactate to pyruvate.  487 
(C) Pyruvate supplementation: Pyruvate is able to counteract substrate decline and 488 
support mitochondrial ATP production in conditions of neuronal stress (only when O2 489 
is present). It also serves as a potent scavenger of reactive oxygen species, reduces 490 
neuroinflammation and subsequent oxidative stress. Pyruvate directly acts within the 491 
blood stream to lower glutamate levels, thereby reducing neuronal calcium (Ca2+) 492 
overload. Pyruvate promotes glycolysis by inhibiting PARP-1 overactivation, which 493 
effectively restores NAD+ levels.  494 
*Adapted from: Zilberter, Y. et al.(2015) A unique array of neuroprotective effects of 495 
pyruvate in neuropathology. Front. Neurosci; 9:17.  496 
 497 
5.3.1.3. Nicotinamide 498 
Nicotinamide adenine dinucleotide (NAD) is a key molecule for mitochondrial health 499 
and nicotinamide (NAM) is a major precursor in the formation of NAD in mammals in 500 
vivo(84,85). NAM is unique among NAD precursors because it is a physiological 501 
inhibitor of the major NAD catabolic enzymes, namely CD38, PARPs (Poly (ADP-502 
ribose) polymerase), and SIRTs (sirtuin)(84,86,87). Its physiological efficacy in 503 
glaucoma is supported by its favourable effects on calcium channel and calcium 504 
signalling (important in axon degeneration) (88–90), its vasoactive properties (with 505 
vascular dysfunction implicated in glaucoma) (91,92) and its ability to improve 506 
endothelial function and stabilising blood flow by reversing endothelin-mediated 507 
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vasoconstriction (with endothelin receptor blockers shown to protect against glaucoma) 508 
(84,93).  509 
 510 
The retinal level of NAD has recently been discovered to decline in an age-dependent 511 
manner(84,94), rendering RGC mitochondria vulnerable to IOP-dependent 512 
stresses(54,95). In a mouse model of hereditary glaucoma (DBA/2J (D2) mice) 513 
Williams et al.(2017) demonstrated that oral administration of nicotinamide and/or gene 514 
therapy (driving expression of Nmnat1, a key NAD+ -producing enzyme) was 515 
protective prophylactically and as an intervention, both histologically and functionally 516 
on pattern electroretinogram(54). More pertinently, up to 93% of eyes did not develop 517 
glaucoma with high dose nicotinamide supplementation, which also had an IOP 518 
lowering effect(54). 519 
 520 
The Wallerian degeneration slow allele, Wlds, deceases the vulnerability of RGCs 521 
subjected to elevated IOP by increasing retinal NAD levels(95). This extends upon the 522 
finding that a mouse strain called Wallerian degeneration slow mice (Wlds ) contains a 523 
spontaneous dominant mutation that protects against neuronal insults, such as 524 
Parkinson’s disease, hypoxic-ischemic injury, toxic neuropathy (taxol), and 525 
others(94,96). Williams et al.(2017) demonstrated that when coupled with nicotinamide 526 
administration, 94% of eyes were protected against glaucomatous neurodegeneration in 527 
a mouse glaucoma model (DBA/2J (D2) mice)(95). Certainly this preliminary evidence 528 
advocates for the use of nicotinamide and/or gene therapy in glaucoma and other 529 
neurodegenerative disease, with further studies required exploring its safety and 530 
efficacy in human disease.  531 
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 532 
5.3.1.4. Lactate and Other Glycolytic Intermediates 533 
Before glucose can reach the retina from the choroidal circulation it must first traverse 534 
the retinal pigment epithelium (RPE), which functions as a blood-retina barrier. Most of 535 
the glucose that reaches the retina is consumed by glycolysis and converted to lactate, 536 
predominantly by photoreceptors. Kanow et.al. (2017) recently demonstrated in in vivo 537 
vertebrate retinas that the lactate converted by photoreceptors serves as a fuel source for 538 
neighbouring retinal cells, and that glycolysis can be suppressed by lactate in RPE cells 539 
to permit more glucose to reach the retina(97).  540 
 541 
It widely accepted that intercellular lactate movement, via monocarboxylate 542 
transporters, performs an essential function in the metabolic interaction between 543 
neurons and glia via the astrocyte-neuronal lactate shuttle. In the CNS it has recently 544 
been demonstrated that lactate has neuroprotective effects in models of excitotoxicity 545 
and energy depletion(98). It appears to constitute an alternative energy substrate for 546 
neurons lacking standard nutrients.  This has been demonstrated in both in vitro and in 547 
vivo models of cerebral ischaemia(98). It has also been proposed that both the L- and D- 548 
forms of lactate play a role in intercellular communication via interaction with the 549 
HCA1 receptor(99). Studies performed by Tekkök et.al. (2005) further support the 550 
hypothesis that L-lactate is released from astrocytes and taken up by axons as an energy 551 
source for sustaining their excitability(100). These findings support the theory that the 552 
metabolic astrocyte-neuronal lactate shuttle within the retina could hold promise for 553 
manipulation in future glaucoma neuroprotection studies.  554 
 555 
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5.3.2. OXPHOS 556 
Mitochondrial aerobic respiration through oxidative phosphorylation (OXPHOS) 557 
generates the majority of ATP in neurons and their axons. Given that OXPHOS, by 558 
definition, is dependent on oxygen and knowing that ischaemia likely plays a role in the 559 
pathogenesis of glaucoma, erythropoietin (EPO) has been proposed as a possible 560 
neuroprotective candidate. EPO is a glycoprotein cytokine secreted by the kidney in 561 
response to hypoxia, which in turn stimulates red blood cell production to improve the 562 
blood stream’s oxygen carrying capacity. EPO and its receptors are distributed within 563 
the human retinal tissue and RPE(101), and Szabo et.al. (2008) demonstrated that RGCs 564 
principally produce and secrete EPO(102). Exogenous EPO administration has been 565 
demonstrated in in vivo glaucoma and optic nerve transection models to improve RGC 566 
survival and restore mitochondrial structure(103–105). Yet a significant draw-back of 567 
EPO therapy is its promotion of angiogenesis causing pathological 568 
neovascularisation(101). Whilst promising pilot studies have been performed looking at 569 
neuroprotection in optic neuritis in humans(106–109), no trials to date have been 570 
undertaken to assess the clinical utility of EPO in glaucoma.  571 
 572 
Neuroglobin (Ngb) is linked to oxidative metabolism and is hypothesised to have a 573 
myoglobin-like role in supplying oxygen to the respiratory chain of neurons whilst also 574 
protecting them from ROS(110). Both Ngb and Cytoglobin are present in distinct nerve 575 
cell populations, including human retinal neurons and RPE(111). In fact, the Ngb 576 
concentration in the retina is 100-fold higher than any other nervous tissues with this 577 
protein being especially abundant (~10-fold higher) in the RGC layer and optic nerves 578 
than in the other layers of the retina(112). Ngb has shown a promising neuroprotectant 579 
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property in murine cerebral and retinal ischaemia(110,113), and has also been found to 580 
prevent RGC damage induced by glutamate cytotoxicity in vitro and/or by chronic IOP 581 
elevation in vivo(114,115). Ngb has not only been demonstrated to improve the survival 582 
of RGCs after optic nerve injury but, in mouse retinas showing enhanced Ngb 583 
expression, was found to regenerate central optic axon outgrowth(116). Ngb may 584 
modulate RGC susceptibility to glaucomatous neural damage and may therefore 585 
represent a novel neuroprotective and neuroregenerative therapy for this disease.  586 
 587 
The general aim of pharmacological therapy in targeting mitochondrial dysfunction in 588 
glaucoma is to improve energy production and protect cells from ROS toxicity(12). A 589 
review of experimental mitochondrial therapies in neurodegenerative disease with 590 
possible translation to optic neuropathies is comprehensively detailed by Lopez 591 
et.al.(2016)(12). Those compounds/therapies targeted against oxidative damage include 592 
mitoquinone mesylate (Mito-Q), co-enzyme Q10 (CoQ10), carotenoids, idebenone, 593 
exogenous glutathione, and methylene blue(12). However, to date there are no clinically 594 
trialled drugs with definitive therapeutic efficacy for the treatment of mitochondrial 595 
dysfunction in glaucoma.  596 
 597 
5.3.3. Pentose Phosphate Pathway (PPP) 598 
Parallel to the glycolytic pathway is the pentose phosphate pathway, taking place in the 599 
cytosol of cells. Using glucose as its primary substrate, the PPP generates NADPH and 600 
pentose sugars as well as ribose 5-phosphate (a precursor for the synthesis of 601 
nucleotides)(117). The production of cellular reducing equivalents can in turn be used in 602 
reductive biosynthesis reactions within cells. NADPH also functions to prevent 603 
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oxidative stress thereby preventing apoptotic cell death(118) and in photoreceptors, this 604 
compound is further involved in the recycling of photopigments(119,120). It has been 605 
hypothesised that glucose can directly provide cytoprotection through its oxidation via 606 
the PPP by maintaining cellular reducing power(117,118).  607 
 608 
Using rat retinal cultures, Han et.al. (2013) demonstrated that administration of the 6-609 
phosphogluconate dehydrogenase inhibitor, 6-AN, inhibited the PPP and reduced the 610 
protective effect of glucose against rotenone-induced retinal cell toxicity(121). Contrary 611 
to this, Winkler et.al. (1997) showed that the portion of total glucose metabolised via 612 
the PPP did not increase significantly in the isolated retina when glucose was elevated 613 
from 5mM to 30mM(122). This suggests that PPP-derived NADPH may only play a 614 
minor role in neuronal functioning. It further supports previous findings that ATP 615 
production from glycolysis constitutes the most important glucose-induced 616 
neuroprotective mechanism in retinal ischaemia(121).  617 
 618 
6. Clinical Translation 619 
Despite large numbers of laboratory-based reports of successful neuroprotection in 620 
animal glaucoma models, clinical translation has been extremely limited. Herein, we 621 
address both the potential reasons underlying this ‘translational gap’ and possible 622 
solutions to this.  623 
 624 
6.1. Who needs neuroprotection? 625 
Currently, the only treatment strategy for glaucoma is reduction of the intraocular 626 
pressure. The basic management algorithm comprises an iterative process of setting a 627 
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target pressure at which it is believed progression will not occur, monitoring the 628 
individual and lowering the target pressure if progression is noted. There is considerable 629 
evidence for the efficacy of this strategy even in individuals with normal-tension 630 
glaucoma(123). Furthermore, there is evidence that if IOP is well controlled at 631 
relatively normal levels then the majority of individuals do not progress(124). However, 632 
the cumulative incidence of bilateral blindness from glaucoma after 20 years is 633 
approximately 14%. Whether or not this incidence could be mitigated or even 634 
eliminated with earlier diagnosis and further reduction of IOP is unclear. Although 635 
robust evidence is not forthcoming, clinical experience suggests that there is a small but 636 
significant group of individuals in whom a target pressure is unreachable even in 637 
principle. In addition, there is a considerable group of individuals who would benefit 638 
from adjunctive treatment where attempting to reach target pressure with more 639 
aggressive treatment may not be desirable. Arguably, a safe, efficacious neuroprotective 640 
therapy as part of a “belt and braces” strategy could be added to the management of all 641 
individuals with glaucoma.   642 
 643 
6.2. Strategies to Advance Clinical Neuroprotection Studies 644 
Obstacles to clinical neuroprotection studies relating to glaucoma include: slow 645 
progression, heterogeneity of pathogenesis, and the fact that evidence of 646 
neuroprotection would need to be detectable beyond the therapeutic effect of routine 647 
IOP reduction. The chronicity of glaucoma and the general slow rate of progression 648 
make clinical neuroprotection studies challenging and potentially prohibitive in terms of 649 
the time and cost required to investigate a new therapy. However, there are strategies 650 
that could considerably reduce the time and sample size required to obtain a definitive 651 
 30 
result. Traditionally, the gold standard primary outcome in clinical glaucoma studies has 652 
been automated perimetry. However, modern practice incorporates optical coherence 653 
tomography (OCT) as a routine clinical tool, with structural changes generally 654 
detectable at an earlier stage than visual field changes. Guided Progression Analysis 655 
(GPA) on the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) provides a trend-based 656 
statistical analysis that could conceivably replace perimetry as a primary outcome in 657 
neuroprotection studies.  658 
 659 
It may be judicious to initially target “lower hanging fruit” where outcomes could be 660 
assessed more rapidly. This could include a randomized controlled trial of 661 
neuroprotectant therapy versus placebo in acute glaucoma or situations where IOP may 662 
be temporarily poorly controlled. Similarly, it would be advantageous to select a sample 663 
of individuals with chronic glaucoma who were rapidly progressing. Identification of 664 
such individuals would be enhanced by large databases at national or international 665 
levels.  666 
 667 
Thoughtful study design and sophisticated statistical analyses can considerably reduce 668 
sample sizes. When obtaining multiple measurements over time comparing rates of 669 
progression between two groups (treated and placebo) where individuals have variable 670 
starting points and rates of progression, the ideal statistical framework is a linear mixed 671 
model incorporating random intercepts and random slopes. This model accounts for the 672 
correlated nature of the data and neatly handles inevitable missing numbers. Estimates 673 
of intercepts, slopes, and correlations can be obtained relatively easily from existing 674 
data. Sample sizes are easily determined using open source software(125).  675 
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 676 
The numbers needed can be surprisingly small. As an example, consider a trial in which 677 
assessments are taken every three months for 24 months (9 visits) and we estimate a 678 
30% reduction in the rate of progression in the group receiving a novel neuroprotectant 679 
compared to the control group. The participants are selected to have a relatively rapid 680 
rate of progression (1 dB per year). We estimate the random intercept to have a variance 681 
of 0.3, the random slope to have a variance of 0.7, and a residual variance of 0.1. The 682 
estimate the correlation between random slope term and random intercept term is 0.7. 683 
Using these estimates, for a power of 80% and alpha value of 0.05, only 46 individuals 684 
are required in each group(126,127). 685 
 686 
7. Conclusion 687 
Glaucoma has a multifactorial pathogenesis, broadly categorised into vascular and 688 
mechanical theories, which drives progressive optic neurodegeneration and consequent 689 
blindness. Thus treatment strategies have evolved based upon potential root causes. 690 
Early identification of those at risk through genetic screening and unveiling the 691 
underlying patient-specific aetiology may, in the future, offer customised therapy 692 
tailored to the individual patient.  693 
 694 
Whilst IOP lowering therapies generally slow the progress of glaucoma progression 695 
they are limited by the extent of their effect despite optimal IOP control. Thus there is 696 
growing demand for, and investment in, neuroprotection research to provide an adjunct 697 
to IOP lowering therapies and prevent visual decline.  698 
 699 
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The holy grail of laboratory glaucoma research would be to develop animal models that 700 
more closely recapitulate human disease in order to validate new therapeutic agents 701 
prior to embarking on human trials. Whilst there is an ever-increasing abundance of 702 
preclinical research, clinical translation remains in early infancy and not without its 703 
inherent challenges. Refinement of clinical trial design and the use of validated home 704 
monitoring techniques may improve the cost burden and efficiency of clinical 705 
neuroprotective trials in glaucoma research. 706 
 707 
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